New Direction Blowing in the Wind for Clean Wind Energy Tower, Inc. (OTCBB: CWET)

Point Roberts WA - October 5, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, releases the following Q&A interview with Ron Pickett, President & CEO of Clean Wind Energy Tower, Inc. (OTCBB: CWET) following recent news from the Company on a change of business direction moving forward.

Q: Investorideas.com
Ron, in your recent press release you stated "the Company is transitioning from a "Research and Development Stage" company to the actual development of our first Dual Renewable Energy Tower project .” For new investors looking at the Company, can you explain the Downdraft tower and the new direction you are taking?
A: Ron Pickett, President & CEO
Our Downdraft Tower is simply a large hollow cylinder located in a very dry area like the Southwestern United States. We spray a fine mist of water near the top of the tower. The hot dry air absorbs the water, which becomes heavier, and sinks downward within the hollow cylinder creating a natural downdraft that is contained inside the tower. Turbines at the base of the tower power generators to make abundant electricity 24/7.
The next direction for the Company is to bring onboard an expert Development Team transitioning the Company from its research stage to actually developing the first Tower. That team will augment the development skills of existing management and combine them with the expertise of internationally recognized engineers, architects and contractors.
Q: Investorideas.com
Why hasn't this technology been deployed previously and how did a small Company like yours get access to it?
A: Ron Pickett, President & CEO
The technology or "technique” of creating a downdraft and containing it to harness wind energy was thoroughly studied by the Technion in Israel decades ago. The key to deployment rests with now proven construction techniques to erect the large tower combined with turbine and generator enhancements to extract maximum power from the downdraft.
Q: Investorideas.com
You also announced a change in share structure and a return to treasury of 120M plus shares . What does that mean to investors?
A: Ron Pickett, President & CEO
The Company recently announced that it had returned 120 million shares to treasury. This simply means that the total number of shares outstanding has been reduced from approximately 330M to 210M. That's about a 50% increase in value per share.
Q: Investorideas.com
What is the scope of a project like this in terms of feasibility, funding and then return on investment?
A: Ron Pickett, President & CEO
The financial feasibility of this project should be excellent. Our target is to present the first Tower project for financing with cash flow to support its debt with a 2:1 coverage. Unlike other "Green” Alternative Energy projects, which need subsidies and special financial incentives, our Tower is designed to be very profitable. The Dual Renewable Energy Tower is a totally "Green” project that generates a lot of "Green” profit.
Q: Investorideas.com
As investors have recently witnessed the failing of large scale solar companies like Solyndra that were funded by Government and investors – how do you differentiate a project on the scale you are undertaking and how are you sure it will succeed?
A: Ron Pickett, President & CEO
As stated above, traditional solar and wind projects need to be subsidized. Not so with our project. We will certainly seek to take advantage of any and all programs for tax-exempt bond financing and for tax and carbon credits. Nevertheless, we anticipate that our first project will be able to generate twice the cash flow before taxes necessary to service the required financing.
Wind Company Snapshot - Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc, is designing and preparing to develop, and construct large " Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies. In addition to constructing Downdraft Towers in the United States and abroad, the Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity. Clean Wind has assembled a team of experienced business professionals, engineers and scientists with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market. Clean Wind has filed several patents that the Company believes will further enhance this potentially revolutionary technology. www.cleanwindenergytower.com
Clean Wind Energy, Inc. Contact:
1997 Annapolis Exchange Parkway Suite 300
Annapolis , Maryland 21401
Phone: 410-972-4713
E-mail: Info@cwetower.com
Visit the CWET showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind and solar stocks
http://www.investorideas.com/Resources/Newsletter.asp
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Follow Investorideas.com on Twitterhttp://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebookhttp://www.facebook.com/Investorideas
Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Investorideas.com contact:
800.665.0411

Visit the CWET showcase page at Investorideas.com:
http://www.investorideas.com/CO/CWE/

Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp

About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.

Sign up at Investor Ideas for free investor alerts including news on wind stocks
http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com

Tuesday's Infrastructure Stocks Trading; (NYSE: BIP), (TSX: CSE), (OTCBB: FRCN), (TSX: ARF)

POINT ROBERTS - October 5, 2011 - www.InvestorIdeas.com, a leader in sector stock research including construction stocks, homebuilder and infrastructure stocks releases the following close-up on small and large cap infrastructure stocks for Tuesday October 4th and why one analyst likes the sector.

ARMTEC INFRASTRUCTURE INC. (Toronto: ARF.TO) closed up at $1.04, up 0.20 (23.81%) on 220,062 shares. The last news reported by the company
POINT ROBERTS - October 5, 2011 - www.InvestorIdeas.com, a leader in sector stock research including construction stocks, homebuilder and infrastructure stocks releases the following close-up on small and large cap infrastructure stocks for Tuesday October 4th and why one analyst likes the sector.
ARMTEC INFRASTRUCTURE INC. (Toronto: ARF.TO) closed up at $1.04, up 0.20 (23.81%) on 220,062 shares. The last news reported by the company was in August, that it had completed a refinancing of its existing senior bank facility. Pursuant to the refinancing, Armtec has borrowed $125 million under a senior secured loan facility with a Brookfield Asset Management Inc. company.

---

Recent commentary in the Globe and Mail quoted fund manager Oscar Belaiche as liking infrastructure stocks “because of their earnings stability from long-term contracts that can be indexed to inflation. He owns pipeline operators such as Enbridge Inc. and TransCanada Corp. as well as utilities such as Northland Power Inc., Innergex Renewable Energy Inc. and Brookfield Renewable Power Fund.”
Fireman's Contractors Inc. (OTCBB: FRCN) reported news Tuesday of a 390% increase in revenue for Fiscal 2011. The CEO of Fireman's Contractors, Renee Gilmore stated, "The past fiscal year was one of tremendous growth for Fireman's Contractors. We raised revenues by 390.59% while significantly expanding our customer base. We contribute our increase in revenues to hard work and dedication as we provided top quality workmanship to our clients. As we move forward in the development and explanation of our business, our goal is to continue building valuable relationships with our clients by providing a high level of professionalism."
The recently listed OTC stock has been trading with a range of $0.11-$0.16.
Capstone Infrastructure Corporation (TSX:CSE ; TSX:CSE.DB.A ; TSX:CSE.PR. A ; on Monday declared its first dividend on its Cumulative 5-Year Rate Reset Preferred Shares, Series A (the "Preferred Shares") of $0.4212 per Preferred Share to be paid on October 31, 2011 to shareholders of record at the close of trading on October 14, 2011. This initial dividend on the Preferred Shares covers the period from June 30, 2011 to October 31, 2011. Future dividends on the Preferred Shares are expected to be $0.3125 quarterly, or $1.25 per share on an annualized basis, for the initial five-year period, which ends on July 31, 2016. The stock closed at $5.88.
Brookfield Infrastructure (NYSE: BIP) (TSX: BIP.UN) closed at $23.00 on just over 1.2 million shares. According to commentary on Motley Fool on Monday its one of five star stocks poised to pop for investors.
Showcase Infrastructure Stock
Visit the company Profile on Investorideas.com
http://www.investorideas.com/CO/FRCN/
About Fireman's Contractors Inc. (OTCBB: FRCN)
Fireman's Contractors Inc. (OTCBB: FRCN) is a full service contractor providing superior service in parking lot maintenance and construction services. Our services include Road Improvements, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, ADA Compliance and other construction services which are delivered at a competitive price. Fireman's brings professional value system delivering outstanding results through honorable customer relationships and repeat business. Local firefighters are supported by a portion of profits which are donated to local Firefighter Associations. http://www.firemans-contractors.com/
Follow FIREMANS CONTRACTORS, Inc. (OTCBB: FRCN) on Twitter.com
http://twitter.com/#!/firemansco
Follow FIREMANS CONTRACTORS, Inc. (OTCBB: FRCN) on Facebook.com
http://www.facebook.com/FiremansContractors
IR Contact info:
Tel: 1(214) 314-1588
Email: invest@firemanscontractors.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising .
Disclosure: Fireman's Contractors Inc. (OTCBB: FRCN) is a paid adverting construction stock on Investorideas.com and blogs (ten thousand for 3 months of advertising)
www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411

Infrastructure Stocks News; Fireman's Contractors (OTCBB:FRCN) Reports 390% Increase in Revenue for Fiscal 2011

FORT WORTH, Texas - October 4, 2011 (Investorideas.com Newswire) Fireman's Contractors Inc. (OTCBB:FRCN.OB) (OTCQB:FRCN.OB) is a full service contractor providing professional services for commercial and government clients in Asphalt Maintenance and Repair, Road Improvements, Seal Coating, Parking Lot Maintenance, and Pavement Marking reported a 390.59% for is Fiscal 2011 year ending June 30th, 2011.

Fiscal 2011 Financial Highlights:
Gross Revenue increased 390.59% in fiscal 2011, July 1st 2010 thru June 30th, 2011.
Key elements for gross revenue increase:

• Continuing efforts to cultivate relationships with commercial clients resulting in 30+% in repeat business
• Our effort in business development to focus on larger government and municipal opportunities
• The addition of our V.P. of Operations, Gary Cochran that helped streamlined productivity
• The addition of our V.P. of Business Development, Steve Winters which allowed the company to increase its business development team, training and take advantage of opportunities in the market

The CEO of Fireman's Contractors, Renee Gilmore stated, "The past fiscal year was one of tremendous growth for Fireman's Contractors. We raised revenues by 390.59% while significantly expanding our customer base. We contribute our increase in revenues to hard work and dedication as we provided top quality workmanship to our clients. As we move forward in the development and explanation of our business, our goal is to continue building valuable relationships with our clients by providing a high level of professionalism."
FIREMAN'S CONTRACTORS Inc. (OTCBB:FRCN.OB) is a full service contractor providing superior service in parking lot maintenance and construction services. Our services include Road Improvements, Seal Coating, Parking Lot Striping, Pavement Marking, Asphalt Maintenance and Repair, ADA Compliance and other construction services which are delivered at a competitive price. Fireman's brings professional value system delivering outstanding results through honorable customer relationships and repeat business. Local firefighters are supported by a portion of profits which are donated to local Firefighter Associations.
To learn more about Fireman's Contractors, please visit our website: http://www.Firemans-Contractors.com
Firefighter and Founder of Fireman's Contractors -- Contractors You Can Trust (R)
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. Additional information respecting the factors that could materially affect the Company and its operations are contained in its annual report on Form 10K and Form 10-Q as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement.
Contact:
FIREMAN'S CONTRACTORS Inc.
2406 Gravel Road
Fort Worth, TX 76118
Phone: 800-475-1479
info@FiremansContractors.com
Investor Relations Contact:
John Pentony, IR Affiliates
Contact: john@iraffiliates.com
Tel: 469.252.3031
Public Relations Contact:
Danielle O'Neal
Contact: PR@FiremansContractors.com
Tel: 800-475-1479
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Twitter.com
http://twitter.com/#!/firemansco
Follow FIREMANS CONTRACTORS, Inc. (OTCBB:FRCN) on Facebook.com
http://www.facebook.com/FiremansContractors

Fireman's Contractors Inc. (OTCBB:FRCN), (OTCQB:FRCN.OB) is a featured construction stock on Investorideas.com

Visit the company profile to learn more: http://www.investorideas.com/CO/FRCN/

Disclaimer/ Disclosure: FRCN has compensated Investorideas.com ten thousand for three months of advertising. All info published is sourced from public files or the Company. This is not a solicitation go buy or sell securities.

Biotech/Pharma Investor Alert; BioSante (NASDAQ: BPAX) Trading up over 10% on News of Top LibiGel efficacy trial results

Point Roberts, WA; LINCOLNSHIRE, Ill - October 4, 2011 - Investorideas.com, a leader in sector stock research for independent investors , issues a trading alert for specialty biotech/ pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), following news released from the Company October 4th.
The stock has bounced back as high as $2.25 in today's trading and is up 10.94% on news of completion of its two pivotal LibiGel (testosterone gel) efficacy trials.
According to reports on Seeking Alpha, "5 Stocks Trading Under $10 That Could Surge Higher", there is more upside for the stock.

News Excerpt: Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Completes Both Pivotal LibiGel® Efficacy Trials
"LINCOLNSHIRE, Ill. - October 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company's anticipated LibiGel new drug application (NDA). The final visit of the last subject enrolled in the second of the two pivotal LibiGel Phase III efficacy trials occurred at the end of September. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.
Data are being collected from the 141 investigative sites in the U.S. and Canada that participated in the two trials, and BioSante expects to announce top-line LibiGel efficacy results during this quarter. Both efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA). The third and last pivotal study for the LibiGel clinical development program is the ongoing LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of 3,656 subjects. The primary analysis of safety data is targeted for third quarter of 2012. The LibiGel NDA submission will include data from the two efficacy trials as well as the safety study and is targeted for the fourth quarter of 2012."
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/10041.asp
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com .
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact BioSante:
For info about BioSante Pharmaceuticals, Inc
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com :
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com
800 665 0411 cvanzant@investorideas.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com

Biotech and Pharma stocks News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Completes Both Pivotal LibiGel® Efficacy Trials


LINCOLNSHIRE, Ill. - October 4, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced completion of its two pivotal LibiGel (testosterone gel) efficacy trials, required for the company's anticipated LibiGel new drug application (NDA). The final visit of the last subject enrolled in the second of the two pivotal LibiGel Phase III efficacy trials occurred at the end of September. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.

Data are being collected from the 141 investigative sites in the U.S. and Canada that participated in the two trials, and BioSante expects to announce top-line LibiGel efficacy results during this quarter. Both efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA). The third and last pivotal study for the LibiGel clinical development program is the ongoing LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of 3,656 subjects. The primary analysis of safety data is targeted for third quarter of 2012. The LibiGel NDA submission will include data from the two efficacy trials as well as the safety study and is targeted for the fourth quarter of 2012.
"We are delighted to have completed both LibiGel Phase III efficacy trials. We appreciate the diligence of the investigative sites and their care of the subjects in the trials, and we also thank the participating subjects," noted Joanne Zborowski, BioSante's vice president of clinical development. "There were over 1,100 subjects enrolled in the two efficacy trials, and we look forward to analyzing the data and announcing the results later this year."
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The completed Phase III efficacy trials are double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from HSDD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States, in surgically menopausal women distressed by their low sexual desire and activity.
In addition, BioSante is conducting the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that has completed enrollment of 3,656 women and has accrued over 4,800 women-years of exposure, to date. The study will continue for a total of five years; however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to demonstrate the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval of LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the fourth quarter of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to its future operations and products, the timing of anticipated clinical development milestones and regulatory submissions and other statements identified by words such as �anticipates,� �expects,� �will,� �continue,� �could,� �believes,� �intends,� �estimates,� �may,� other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, 312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com

The Renewable Energy Stock That Could... Ener1 Inc (NasdaqGS: HEV) Momentum Continues as Stock Moves over 23% in Morning Trading

Point Roberts, WA - October 4, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, issues a morning trading alert for Ener1 Inc (NasdaqGS: HEV). The stock has been on the run for days and continues its gains in todat's morning session, trading at $0.2298, up another 0.0443 (23.88%) 10:15AM EDT.

Ener1 Inc (NasdaqGS: HEV) is one of the renewable energy stocks that had been battered to its lows with lawsuits, and losses from its 52 week-high of $5.90. The Company has recently announced changes in management and is obviously on a new path with new leadership. Is this a sign and signal for some of the other companies in the sector, in particular some of the solar stocks?
According to our solar expert J Peter Lynch in his commentary yesterday, he is still optimistic for the future of solar stocks and solar technology and he thinks the stocks will tell investors the time to buy . Read yesterday's article : http://www.investorideas.com/PL/news/ 2011/10031.asp
5 Day chart for HEV
Use the renewable energy stocks directory to research 1300 green stocks on global stock exchanges http://www.investorideas.com/Companies/ RenewableEnergy/Stock_List.asp
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit Investorideas.com green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/ RenewableEnergy/ or www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks onFacebook.com
http://www.facebook.com/renewableenergystocks
Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com contact:
800.665.0411

Pharma/Biotech Stock (OTC: AEMD) Doubles During Monday's Trading Following Report of $6.8 Million DARPA Contract


Point Roberts, WA - October 4, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, reports Aethlon Medical (OTCBB: AEMD) stock traded up over 100% , as high as $0.12 in yesterday's trading session following news of a $6.8 Million DARPA contract.

The stock traded significant volume and was one of the top ten percentage gainers on OTCBB throughout the day’s trading session on larger than normal trading volume. (See 5-day chart)
The Company reported yesterday that it has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. The contract program will utilize the Aethlon ADAPT™ system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.
Biotech Investor Snapshot for Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon's ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C. For more information, please visit www.aethlonmedical.com.
Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/ AEMD
Get biotech news and stock alerts
http://www.investorideas.com/Resources/ Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/ Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011       
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page

Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

Monday's NASDAQ Winners: IIN, PPDI, MDCO, HEV

POINT ROBERTS - October 4, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday October 03rd. Nasdaq ended lower by 79.57 (-3.29%) to 2,335.83.

Yes investors, there are still winners even on another dismal day of market retreat.
IntriCon Corporation (NASDAQ:IIN) was the top percentage gainer for the session closing higher by 1.07 (34.85%) to $4.14 after the company announced it has entered into a manufacturing agreement to become hi HealthInnovations' supplier of hearing aids.
Pharmaceutical Product Development (NASDAQ:PPDI) surged 6.62 (25.80%) to close at $32.28 after the company agreed to go private affiliates of Carlyle Group and Hellman & Friedman for $3.9 billion, payable in cash.
The Medicines Company (NASDAQ:MDCO) closed with an impressive gain of 1.72 (11.56%) to end the day at $16.60 after it announced launch of a new twelve hour formulation for Cleviprex® (clevidipine) Injectable Emulsion, which was approved by the U.S. Food and Drug Administration (FDA) in June 2011. The stock is continuing its gains in early morning trading.
Renewable energy stock, Ener1, Inc. (NASDAQ:HEV) continued to move higher and ended at $0.185, up 0.12 049(35.40%). The stock has more than doubled in the past couple of trading sessions on sharp bounce back from its lows.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Biotech Stock News Alert; (OTC: AEMD) Trading Up 50.88% on News of $6.8 million Contract from Defense Advanced Research Projects Agency (DARPA)

Point Roberts, WA - October 3, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, report Aethlon Medical (OTCBB: AEMD), a pioneer in developing therapeutic filtration devices is trading up at $0.0860, up 0.0290 (50.88%) on over 1.3 million shares in early morning trading.
The Company reported news that it has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. The contract program will utilize the Aethlon ADAPT™ system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.
Biotech Investor Snapshot for Aethlon Medical (OTCBB: AEMD)

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Aethlon's ADAPT™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as HIV and Hepatitis C. For more information, please visit www.aethlonmedical.com.
Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/ AEMD
Get biotech news and stock alerts
http://www.investorideas.com/Resources/ Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/ Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011       
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page

Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

Friday's NASDAQ Winners: CISG, AMSC, INFI, CAMP

POINT ROBERTS - October 3, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Friday September 30th. Nasdaq ended lower by 65.36 (-2.63%) to close at 2,415.40.

CNinsure Inc. (NASDAQ:CISG) was the top percentage gainer for the session closing higher by 1.06 (17.85%) to $7 as it bounced back from its 52-week low of $5.81. Volume was heavy with more than 780K shares traded, compared to its average volume of 725K shares. The Company distributes a wide variety of property and casualty and life insurance products underwritten by domestic and foreign insurance companies operating in China, and provides insurance claims adjusting as well as other insurance-related services.
Insurance stocks have been in the top NASDAQ gainers over the past few weeks with companies like Harleysville Group Inc. (NASDAQ:HGIC) announcing mergers.
American Superconductor Corporation (NASDAQ:AMSC) moved up 0.36 (12.63%) to close at $3.21. The company reported that it earned 11 cents a share on revenue of $33.8 million, compared to analysts’ estimates of 3 cents a share on revenue of $33.38 million.
The company projects to earn $30-$34 million in revenue for the current quarter.
Infinity Pharmaceuticals Inc (NASDAQ:INFI) closed with a gain of 0.71 (11.20%) to end the day at $7.05, bouncing back from its recent fall of 8% during the past week.
CalAmp Corp. (NASDAQ:CAMP) continued to move higher and ended at $3.21, up 0.36 (12.63%) after rallying about 6% in the previous trading session. The stock has a 52-week range of $2.34-$3.98.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas
Real time alerts, stock directories, investing ideas
Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com

Friday's Electric Car Stocks Trading; (OTC: EVCA), (NASDAQ: HEV), (OTC: LMCO), (NASDAQ: TSLA)

Point Roberts, WA - October 3, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, reports on microcap, small cap and large cap electric car stocks trading for Friday30th September.

Ener1, Inc. (NASDAQ:HEV) was the biggest gainer and soared 52.22% to $0.137, bouncing from its recent lows on heavy volume of 10.19 million shares - 5X its average volume. The stock continues its gains in Monday morning trading, up another 7%.
EVCARCO (OTCBB: EVCA ) shares ended flat at 0.0024 with 100K shares traded hands. The Company is engaged in selling environmentally conscious automobiles, offering both new electric and pre-owned vehicles, and plan to offer related financing, warranties, maintenance, and mechanical services.
Li-ion Motors Corp (OTC:LMCO) was one of the biggest gainers and surged 0.030 (13.64%) to $0.25 with more than 61K shares traded hands, 1.50X its average volume. The stock has a 52-week range of $0.14-$1.20.
Tesla Motors, Inc. (NASDAQ: TSLA) gained 0.27 (1.12%) to $24.39 on over 1.33 million shares.
Cambria Automobiles PLC (LON:CAMB) surged 1.00 (4.17%) to $25.
Valence Technology, Inc. (NASDAQ:VLNC) added 0.04 (4.00%) to $1.04
Electric Car/ Green Car Company Snapshot
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
Visit the EVCA profile at Investorideas.com - http://www.investorideas.com/CO/EVCA/
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp
Follow Renewable Energy Stocks on Facebook.com
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp , http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information contact:
800 665 0411
Source: www.Investorideas.com

Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Receives Government Contract Award from DARPA

SAN DIEGO � October 3, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. The contract program will utilize the Aethlon ADAPT™ system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. The resulting device, which is being advanced under DARPA's Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.

"We are truly honored to receive this contract award and look forward to working with DARPA and other DLT team participants to advance this important therapeutic endeavor," stated Aethlon Medical Chairman and CEO, Jim Joyce. "The award also reinforces the expansive capabilities of our ADAPT™ system, increases the breadth of our product pipeline, and transitions us from a development-stage to revenue-stage organization."
The Aethlon ADAPT™ system, introduced earlier this year, is an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that selectively target the clearance of harmful agents from the entire circulatory system without the loss of essential blood components. Therapies that evolve from the Aethlon ADAPT™ system overcome the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity drug agents in the outer-capillary space of plasma membrane technology as a means to provide rapid real-time clearance of corresponding targets without adding drug toxicity or interaction risks to established therapies. Beyond providing a novel regulatory and commercialization pathway for affinity drug agents, Aethlon ADAPT™ therapies can be implemented for use within the global infrastructure of dialysis machines and CRRT systems already located in hospitals and clinics. As Aethlon advances its current pipeline of therapies toward market, the company will seek to further leverage its ADAPT™ system to generate revenue through future government contracts or grants, and collaborations with organizations representing the pharmaceutical, biotechnology and medical device industry. The Aethlon award from DARPA is a fixed price five-year contract valued at $6,794,389 with year one revenues of approximately $2 million.
About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page

Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

Pharma/Biotech stocks News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Cancer Immunotherapy Conference

LINCOLNSHIRE, Ill. - October 3, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 6, 2011, at the New York Academy of Medicine in New York. The single-day conference event unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy.

Stephen M. Simes, BioSante's president & chief executive officer, will speak at 1:45 pm EDT, and will provide an overview of BioSante's portfolio of cancer vaccines currently in multiple Phase II clinical trials.
The conference will be hosted by MD Becker Partners and sponsored by JMP Securities, Thompson Hine, Roth Capital Partners and Cantor Fitzgerald. There will be a corresponding live webcast of the presentations, which can be accessed by visiting www.regonline.com/mdbpartners. A replay will be available for 30 days.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
About MD Becker Partners
MD Becker Partners LLC is a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry. As a strategic advisor and partner, the firm provides a full range of services to help clients increase visibility, unlock stakeholder value and access resources to grow their business. To accomplish this, MD Becker Partners integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information visit www.mdbpartners.com.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, 312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com